Sanofi Gestione

Gestione criteri di controllo 3/4

Sanofi Il CEO è Paul Hudson, nominato in Sep2019, e ha un mandato di 5.17 anni. la retribuzione annua totale è € 10.57M, composta da 13.2% di stipendio e 86.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.006% delle azioni della società, per un valore di € 6.60M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 4.6 anni.

Informazioni chiave

Paul Hudson

Amministratore delegato

€10.6m

Compenso totale

Percentuale dello stipendio del CEO	13.2%
Mandato del CEO	5.2yrs
Proprietà del CEO	0.006%
Durata media del management	4.3yrs
Durata media del Consiglio di amministrazione	4.6yrs

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Hudson rispetto agli utili di Sanofi?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	€5b
Jun 30 2024	n/a	n/a	€4b
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 11.01M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 4.78M ).

Compensazione vs guadagni: La retribuzione di Paul è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Paul Hudson (57 yo)

5.2yrs

Mandato

€10,571,822

Compensazione

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Hudson	CEO & Director	5.2yrs	€10.57m	0.0056% € 6.6m
François-Xavier Roger	Executive VP & CFO	less than a year	Nessun dato	Nessun dato
Madeleine Roach	Executive VP & Head of Business Operations	1.1yrs	Nessun dato	Nessun dato
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	Nessun dato	Nessun dato
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	Nessun dato	Nessun dato
Thomas Larsen	Head of Investor Relations	less than a year	Nessun dato	Nessun dato
Dante Beccaria	Global Compliance Officer & VP	12.6yrs	Nessun dato	Nessun dato
Roy Papatheodorou	Executive VP & General Counsel	2.8yrs	Nessun dato	Nessun dato
Josep Catlla	Head of Communications	no data	Nessun dato	Nessun dato
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	20.3yrs	Nessun dato	Nessun dato
Natalie Bickford	Executive VP & Chief People Officer	4.3yrs	Nessun dato	Nessun dato
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22.5yrs	Nessun dato	Nessun dato

4.3yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di SNW2 è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Hudson	CEO & Director	5.1yrs	€10.57m	0.0056% € 6.6m
Jean-François Dehecq	Honorary Chairman	14.5yrs	€4.71m	Nessun dato
Serge Weinberg	Honorary Chairman	1.5yrs	€324.96k	0.00013% € 151.8k
Patrick Kron	Independent Director	10.5yrs	€175.75k	0.000080% € 93.4k
Lise Kingo	Independent Director	4.6yrs	€148.25k	0.000080% € 93.4k
Frederic Oudea	Independent Chairman	1.5yrs	€573.52k	0.000080% € 93.4k
Fabienne Lecorvaisier	Independent Director	11.5yrs	€156.50k	0.000080% € 93.4k
Gilles Schnepp	Independent Director	2.9yrs	€175.75k	0.000080% € 93.4k
Rachel Duan	Independent Director	4.6yrs	€145.50k	0.000080% € 93.4k
Barbara Lavernos	Director	3.6yrs	€134.50k	0.000080% € 93.4k
Christophe Babule	Director	5.8yrs	€134.50k	0.000080% € 93.4k
Wolfgang Laux	Employee Representative Director	3.6yrs	€107.00k	0.00031% € 362.1k

4.6yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SNW2 sono considerati esperti (durata media dell'incarico 4.6 anni).

Sanofi Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media